We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+9.67%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$98.6B
AUM Growth
+$9.82B
Cap. Flow
+$3.18B
Cap. Flow %
3.23%
Top 10 Hldgs %
34.51%
Holding
3,532
New
899
Increased
935
Reduced
953
Closed
698

Top Buys

Rank Stock Value
1
IVV icon
iShares Core S&P 500 ETF
IVV
+$3.93B
2
MSFT icon
Microsoft
MSFT
+$556M
3
COR icon
Cencora
COR
+$492M
4
NFLX icon
Netflix
NFLX
+$452M
5
BAC icon
Bank of America
BAC
+$411M

Sector Composition

Rank Sector Weight
1 Technology 20.19%
2 Consumer Discretionary 12.64%
3 Healthcare 9.35%
4 Financials 8.34%
5 Communication Services 6.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BLK icon
2226
Blackrock
BLK
$170B
$471K ﹤0.01%
+404
New +$452K
ACOG
2227
Alpha Cognition
ACOG
$186M
$470K ﹤0.01%
72,212
+7,887
+12% +$71.9K
GXO icon
2228
GXO Logistics
GXO
$5.91B
$470K ﹤0.01%
8,884
+2,766
+45% +$142K
IMUX icon
2229
Immunic
IMUX
$175M
$469K ﹤0.01%
53,352
+48,353
+967% +$426K
TV icon
2230
Televisa
TV
$1.46B
$468K ﹤0.01%
+173,992
New +$439K
HURC icon
2231
Hurco Companies Inc
HURC
$131M
$467K ﹤0.01%
+26,849
New +$496K
CHMG icon
2232
Chemung Financial Corp
CHMG
$396M
$466K ﹤0.01%
8,874
-5,913
-40% -$308K
CTKB icon
2233
Cytek Biosciences
CTKB
$563M
$466K ﹤0.01%
134,286
-127,066
-49% -$477K
TLX
2234
Telix Pharmaceuticals
TLX
$3.42B
$465K ﹤0.01%
+48,573
New +$595K
WTS icon
2235
Watts Water Technologies
WTS
$11.2B
$464K ﹤0.01%
+1,662
New +$446K
WMT icon
2236
PUT
Walmart Inc
WMT
$907B
$464K ﹤0.01%
4,500
-402,700
-99% -$40.1M
WRB icon
2237
W.R. Berkley
WRB
$28.1B
$463K ﹤0.01%
6,045
-172,700
-97% -$12.3M
CLYM
2238
Climb Bio
CLYM
$701M
$462K ﹤0.01%
229,889
+193,151
+526% +$359K
SMLR
2239
DELISTED
Semler Scientific
SMLR
$461K ﹤0.01%
+15,372
New +$529K
ENPH icon
2240
PUT
Enphase Energy
ENPH
$4.85B
$460K ﹤0.01%
+13,000
New +$483K
EWZ icon
2241
PUT
iShares MSCI Brazil ETF
EWZ
$9B
$459K ﹤0.01%
+14,800
New +$424K
WHF icon
2242
WhiteHorse Finance
WHF
$139M
$456K ﹤0.01%
65,850
+23,610
+56% +$202K
ONCY
2243
Oncolytics Biotech
ONCY
$89.5M
$454K ﹤0.01%
+323,982
New +$363K
HMC icon
2244
Honda
HMC
$39.9B
$451K ﹤0.01%
14,652
-11,578
-44% -$378K
REGN icon
2245
PUT
Regeneron Pharmaceuticals
REGN
$72.9B
$450K ﹤0.01%
+800
New +$452K
ALEC icon
2246
Alector
ALEC
$171M
$449K ﹤0.01%
+151,643
New +$334K
GTN icon
2247
Gray Television
GTN
$437M
$446K ﹤0.01%
77,200
FPH icon
2248
Five Point Holdings
FPH
$393M
$445K ﹤0.01%
72,625
+39,791
+121% +$231K
WSBF icon
2249
Waterstone Financial
WSBF
$372M
$444K ﹤0.01%
+28,431
New +$407K
PLRX icon
2250
Pliant Therapeutics
PLRX
$66.3M
$443K ﹤0.01%
+299,461
New +$457K

Similar funds

Marshall Wace's Q3 2025 Portfolio in Review

As of Q3 2025, Marshall Wace held 3,532 positions worth $98.6B, up 11% from $88.8B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Marshall Wace deployed $3.18B of net new capital in Q3 2025, opening 899 new positions and adding to 935 existing holdings. Its largest new stake was Texas Instruments: 1,537,539 shares worth $282M.

By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Healthcare.

On the sell side, the largest reduction was Alphabet (Google) Class A, an estimated $636M trimmed.

  • Marshall Wace's largest Q3 2025 buy was Texas Instruments: 1,537,539 shares worth $282M.
  • Marshall Wace added most to iShares Core S&P 500 ETF in Q3 2025, an estimated $3.93B increase.
  • Marshall Wace's biggest Q3 2025 reduction was Alphabet (Google) Class A, cutting an estimated $636M.
  • Marshall Wace fully exited AT&T in Q3 2025, selling an estimated $235M.
  • Marshall Wace's ten largest holdings make up 35% of its $98.6B portfolio in Q3 2025.
  • Marshall Wace opened 899 new positions and closed 698 in Q3 2025.
  • Marshall Wace's portfolio value rose 11% quarter-over-quarter to $98.6B.

Based on Marshall Wace's 13F filing for Q3 2025, filed 13 Nov 2025.